RRP is a rare disease caused primarily by HPV-6 and HPV-11, characterized by wart-like growths in the respiratory tract that can cause airway obstruction and voice impairment. The current standard of ...

Please note that all scripts are fully protected by copyright law. All scripts are available only for private, personal use and not for any other form of wider distribution. You are not allowed to ...

BSE has imposed new surveillance measures on nine stocks, including RRP Semiconductors, which has recently been in the news for its unusual price run. In a circular issued on Friday, BSE stated: “In ...

New Delhi: Bombay Stock Exchange (BSE) has imposed a new weekly trading surveillance measure on nine stocks, including RRP Semiconductors, to address excessive volatility following unusual price ...

The Bombay Stock Exchange (BSE) has issued a warning to investors about RRP Semiconductor Ltd after the company’s stock rose more than 12,500% in the past year amid misinformation circulating on ...

Dalal Street thrives on surprises, but few have been as dramatic as the sudden rise of Rajendra Kamalakant Chodankar. Once an obscure name in market circles, Chodankar has found himself vaulted into ...

RRP Semiconductor has stunned Indian markets with a staggering 61,848% surge in its share price over just 18 months — but now, stock exchange BSE is stepping in with a red flag for investors. From ₹15 ...

QT endgame gains urgency as Fed's RRP usage nears zero Fed's balance sheet shrinks from $9 trillion to $6.6 trillion Powell warns against removing Fed's interest-paying powers Oct 14 (Reuters) - ...

RRP Electronics Ltd. has announced the signing of four Memorandums of Understanding (MoUs) aimed at strengthening India’s domestic semiconductor ecosystem while positioning the country as a trusted ...

Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa ...

Zopapogene imadenovec-drba is the first FDA-approved therapy for adult recurrent respiratory papillomatosis, targeting HPV types 6 and 11. The pivotal study demonstrated a 51% complete response rate, ...

Papzimeos, the first-ever treatment approved for RRP is a moment for celebration and reflection The Recurrent Respiratory Papillomatosis Foundation (RRPF) is excited to share the news that the U.S.